BioSyent Pharma Submits Two New Drugs to Health Canada for Marketing Approval
TORONTO, ONTARIO--(Marketwired - May 23, 2013) - BioSyent Inc. (TSX VENTURE:RX) ("BioSyent") is pleased to announce that its subsidiary, BioSyent Pharma Inc., has submitted two new drug products to Health Canada seeking marketing approval.
These two urgent care drugs are supplied in a patented delivery system that offers technical advantages over existing alternatives and will be used in hospitals and acute care settings. These products will provide hospitals, clinics, and healthcare professionals with improved patient safety as well as operational efficiencies and will complement BioSyent's Hospital Division.
"These two products are consistent with our strategy of sourcing unique and innovative pharmaceutical products for the Canadian market," said René Goehrum, President and CEO of BioSyent. "There are additional products under development by our European partner and we look forward to exploring additional product candidates utilizing the same patented technology. Due diligence on the next product has already commenced."
The products will be launched after Health Canada grants marketing approval.
For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.
About BioSyent Inc.
Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.
Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.
At the date of this press release the Company had 13,571,195 shares issued and outstanding.
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
Contact:
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
(905) 206-0013
investors@biosyent.com
www.biosyent.com
Mike
SwingTrade is my favorite board - #board-1781
Due diligence on my favorite stocks is located on the sticky note on the SwingTrade board.
